Introduction
============

Insulin-like growth factor II mRNA-binding protein 3 (IMP3 or IGF2BP3) is a member of the RNA-binding protein family, which plays an important role in RNA trafficking and stabilization, cell growth, and cell migration during the early stages of embryogenesis.[@b1-ott-10-2849] IMP3 was proposed to control the translation or turnover of various candidate target genes, including IGF2, CD44, HMGA2, and MMP9.[@b2-ott-10-2849]--[@b5-ott-10-2849] This oncofetal protein has been reported to promote tumor cell survival, proliferation, chemoresistance, and tumor cell invasiveness in vitro. In recent years, accumulating studies have shown that IMP3 is specifically expressed in malignant tumors and acts as an important cancer-specific gene involved in many aggressive and advanced cancers.[@b6-ott-10-2849],[@b7-ott-10-2849]

Numerous studies have reported that upregulated IMP3 expression in tumor tissues is correlated with poor patient survival and can be used as a prognostic factor to guide clinical decisions and distinguish different prognoses in various solid tumors, such as renal cell carcinoma (RCC), lung cancer, oral cancer, bladder cancer, gastrointestinal tumors, and gynecological tumors.[@b8-ott-10-2849]--[@b13-ott-10-2849] However, some other studies have reported the absence of association between IMP3 expression and cancer prognosis.[@b14-ott-10-2849],[@b15-ott-10-2849] Some investigators have also replayed completely opposite results in ovarian cancer. For instance, Kobel et al[@b16-ott-10-2849] proposed that IMP3 expression is a marker of unfavorable prognosis, whereas Noske et al[@b17-ott-10-2849] asserted that IMP3 expression is associated with improved survival. Hence, the prognostic role of IMP3 expression in solid tumors remains unclear and controversial.

Therefore, we conducted a systematic review of published studies, with a standard meta-analysis combining available evidence, to evaluate the prognostic value of IMP3 expression in solid tumors.

Materials and methods
=====================

This meta-analysis was conducted according to the guideline of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)[@b18-ott-10-2849] ([Table S1](#SD1-ott-10-2849){ref-type="supplementary-material"}). Because the data included in this study were retrieved from published articles, ethical approval from ethics committees was not needed.

Literature search
-----------------

A comprehensive literature search was performed in PubMed, Embase, Web of Science, and Cochrane Library to identify studies evaluating IMP3 expression and clinical prognosis in solid tumors up to April 2016. The search strategy included the following terms through MeSH headings, keywords, and text words: "IMP3" or "Insulin-like growth factor 2 mRNA binding protein 3" or "IGF2BP3" combined with "cancer" or "carcinoma" or "neoplasm". The references cited in the identified articles were also screened for possible inclusions. The database search and preliminary evaluation of identified studies were performed independently by two investigators (LC and YX). No language limitation existed in the process.

Study selection
---------------

The inclusion criteria for selecting articles in our analysis are listed as follows: 1) studies that reported IMP3 expression in cancer tissues, 2) studies analyzing the relationship between IMP3 expression level and clinical cancer outcomes, 3) studies that directly reported survival outcomes with hazard ratio (HR) and corresponding 95% confidence interval (CI) or studies that provided sufficient data for estimating HR and 95% CI by using the methods described by Tierney et al,[@b19-ott-10-2849] and 4) studies with a median follow-up of at least 6 months. Studies were excluded if they were 1) case reports, letters, conference abstracts, or reviews, 2) non-human research, 3) investigations on the diagnostic role, but not the prognostic role, of IMP3, and 4) studies with insufficient data for calculating the HR and 95% CI. If duplicate publications by the same authors were retrieved, we included only the most informative and recent study. Two independent reviewers (LC and YX) evaluated the full articles for study eligibility, and any disagreement was resolved by consensus.

Data extraction and quality assessment
--------------------------------------

Two authors (LC and YX) independently extracted data from each eligible study by using predefined item forms. The following information, if available, was recorded: first author's name, year of publication, study country or region, type of cancer, cancer stage, number of patients, detected method, cutoff definition, percentage of high IMP3 expression, follow-up period, and survival outcomes with their HRs and corresponding 95% CIs. If univariate and multivariate analyses were reported to obtain the HRs, the results of multivariate analysis were preferentially selected. If HRs and 95% CIs were not provided directly, we attempted to estimate these points with Kaplan--Meier curve or other required data in the original study by using Tierney et al's methods.[@b19-ott-10-2849] Study quality was scored by two investigators (LC and YX) using the Newcastle--Ottawa Scale, which involves three main categories: selection, comparability, and outcome ascertainment. We defined studies with scores no less than 6 as qualified to be included in the meta-analysis. Discrepancies between investigators were resolved through discussion.

Statistical analysis
--------------------

Pooled HRs and corresponding 95% CIs were calculated to evaluate the prognostic role of high IMP3 expression in the clinical outcomes of solid tumors. An observed HR greater than 1 implied a worse prognosis in patients with high IMP3 expression, and an HR less than 1 indicated a better prognosis. Statistical heterogeneity of combined HR was assessed using Cochrane *Q*-test and Higgins *I*^2^ metrics. *I*^2^\>50% was considered a measure of obvious heterogeneity.[@b20-ott-10-2849] If no evident heterogeneity existed, the fixed-effect model (Mantel--Haenszel method) was used to pool the results.[@b21-ott-10-2849] Otherwise, the randomeffect model (DerSimonian and Laird method) was selected.[@b22-ott-10-2849] The potential sources for heterogeneity, if significant, were further explored using a predefined subgroup analysis and meta-regression analysis (based on cancer type, ethnicity, case number, cutoff, cancer stage, HR obtained method, and analysis method). To assess the stability of the pooled results, sensitivity analysis was performed by sequential omission of each single study. Publication bias was also estimated by visually assessing the asymmetry of the funnel plot and then quantitatively evaluated by Begg's and Egger's tests.[@b23-ott-10-2849],[@b24-ott-10-2849] All the abovementioned analyses were performed using STATA version 12.0 (Stata Corporation, College Station, TX, USA). All statistical tests were two sided, and statistical significance was defined as a *P*-value less than 0.05.

Results
=======

Search results and study characteristics
----------------------------------------

The flowchart of the literature search is shown in [Figure 1](#f1-ott-10-2849){ref-type="fig"}. A total of 420 potentially relevant studies were retrieved from the initial literature search in the aforementioned electronic databases. A total of 144 duplicated records were excluded by a literature manager software. After carefully screening titles and abstracts of the remaining 120 records, 46 studies were excluded and 74 studies were selected for full-text assessment. Given the inclusion and exclusion criteria, 21 studies that belonged to duplicate publication or failed to offer sufficient prognostic information were excluded. Finally, 53 studies satisfied our eligibility criteria and were included in this meta-analysis.

The characteristics of these enrolled studies are summarized in [Table 1](#t1-ott-10-2849){ref-type="table"}. The 53 studies involved 8,937 patients with different cancer types, including 6 studies of RCC,[@b8-ott-10-2849],[@b25-ott-10-2849]--[@b29-ott-10-2849] 6 lung cancer,[@b9-ott-10-2849],[@b30-ott-10-2849]--[@b34-ott-10-2849] 4 oral cancer,[@b10-ott-10-2849],[@b35-ott-10-2849]--[@b37-ott-10-2849] 4 urothelial carcinoma,[@b38-ott-10-2849]--[@b41-ott-10-2849] 4 ovarian cancer,[@b16-ott-10-2849],[@b17-ott-10-2849],[@b42-ott-10-2849],[@b43-ott-10-2849] 3 hepatocellular carcinoma (HCC),[@b44-ott-10-2849]--[@b46-ott-10-2849] 4 colorectal cancer,[@b12-ott-10-2849],[@b47-ott-10-2849]--[@b49-ott-10-2849] 3 prostate cancer,[@b14-ott-10-2849],[@b15-ott-10-2849],[@b50-ott-10-2849] 3 pancreatic cancer,[@b51-ott-10-2849]--[@b53-ott-10-2849] 2 gastric cancer,[@b11-ott-10-2849],[@b54-ott-10-2849] 2 intrahepatic cholangiocarcinoma (ICC),[@b55-ott-10-2849],[@b56-ott-10-2849] and one study each of tongue cancer,[@b57-ott-10-2849] thyroid carcinoma,[@b58-ott-10-2849] sacral chordoma,[@b59-ott-10-2849] pilocytic astrocytoma and pilomyxoid astrocytoma (PA/PMA),[@b60-ott-10-2849] neuroblastoma,[@b61-ott-10-2849] meningioma,[@b62-ott-10-2849] melanoma,[@b63-ott-10-2849] breast cancer,[@b64-ott-10-2849] giant cell tumor,[@b65-ott-10-2849] bile duct carcinoma,[@b66-ott-10-2849] esophageal carcinoma,[@b67-ott-10-2849] and cervical cancer.[@b13-ott-10-2849] A total of 25 studies involved Caucasians and 28 involved Asians. The survival outcomes in these studies, including overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), recurrence-free survival (RFS), progression-free survival (PFS), and metastasis-free survival (MFS), were investigated in 40, 10, 8, 7, 4, and 5 studies, respectively. HRs were reported directly in most of these studies (43/53) and were estimated indirectly in the 10 other studies. Multivariate Cox analysis was performed to evaluate the prognostic role of IMP3 in 38 studies; and univariate analysis was conducted in the other 15 studies. Immunohistochemistry (IHC) staining and quantitative polymerase chain reaction (qPCR) were used to test the IMP3 expression in cancer tissues. Notably, the definition and cutoff of high IMP3 expression were heterogeneous among these studies. The majority of included studies used the percentage of positive staining cells (0%, 10%, 25%, or 50%) as the criteria, whereas in some other studies, staining scores with the percentage and intensity score were obtained as cutoff values for high IMP3 expression. The percentage of high expression in the cohort population varied in different cancer types and ranged from 6.5% to 83.3%. Quality score assessment suggested that the scores of enrolled studies ranged from 6 to 9, which were considered adequate for quantitative meta-analysis.

Association of IMP3 with OS
---------------------------

The association of IMP3 expression and OS was investigated in 40 studies containing 6,425 patients with different cancer types. A random-effect model was selected because of the evident interstudy heterogeneity (*I*^2^=59.1%, *P*=0.005). Combined analysis revealed that high IMP3 expression was associated with the worse OS of solid tumors (HR =2.08, 95% CI: 1.80--2.42, *P*\<0.001, [Figure 2](#f2-ott-10-2849){ref-type="fig"}). The effect of IMP3 expression on OS was further analyzed by tumor types, and the results are presented in [Figure 3A](#f3-ott-10-2849){ref-type="fig"}. High IMP3 expression was significantly associated with poor OS in RCC (HR =2.80, 95% CI: 1.59--4.93, *P*\<0.001), lung cancer (HR =1.87, 95% CI: 1.22--2.84, *P*=0.004), oral cancer (HR =1.66, 95% CI: 1.27--2.18, *P*\<0.001), urothelial carcinoma (HR =1.92, 95% CI: 1.42--2.59, *P*\<0.001), HCC (HR =2.25, 95% CI: 1.65--3.06, *P*\<0.001), colorectal cancer (HR =1.52, 95% CI: 1.23--1.90, *P*\<0.001), pancreatic cancer (HR =3.54, 95% CI: 2.06--6.09, *P*\<0.001), gastric cancer (HR =2.67, 95% CI: 1.38--5.17, *P*=0.003), and ICC (HR =2.10, 95% CI: 1.52--2.92, *P*\<0.001) but not in ovarian cancer (HR =1.05, 95% CI: 0.18--6.15, *P*=0.957). To explore the source of heterogeneity, subgroup analysis and meta-regression were performed by the following stratification: patient ethnicity, study number, cutoff value, cancer stage, HR obtained method, and analysis style ([Table 2](#t2-ott-10-2849){ref-type="table"}). The results indicated that the combined HR estimates for OS in Caucasians and Asians were 2.08 (95% CI: 1.54--2.81, *P*\<0.001) and 1.96 (95% CI: 1.73--2.22, *P*\<0.001), respectively. Differences in the case number, cutoff value, cancer stage, HR obtained method, and analysis method did not influence the effect of IMP3 expression on the OS of solid tumors. Further meta-regression analysis revealed that cancer stage is a potential significant contributor to heterogeneity (*P*=0.017), unlike other factors (*P*\>0.05).

To assess the credibility of the pooled outcomes, we performed a sensitivity analysis through the sequential omission of individual studies. The results were not obviously influenced by any single study ([Figure 3C](#f3-ott-10-2849){ref-type="fig"}). The publication bias of all included studies was evaluated using a vertical funnel plot, Begg's, and Egger's tests. However, the funnel plot in [Figure 3B](#f3-ott-10-2849){ref-type="fig"} appears asymmetrical, and the Begg's (*P*=0.015) and Egger's tests (*P*=0.002) revealed existing evidence of publication bias, which may be attributed to only seven studies that reported negative results among all the enrolled studies.

Association of IMP3 with CSS, DFS, RFS, PFS, and MFS
----------------------------------------------------

Ten studies that involved a total of 2,877 patients provided sufficient data for CSS analysis. No heterogeneity was observed among these studies (*I*^2^=31.3%, *P*=0.158). Thus, a fixed model was applied to pool the results. The combined HR was 1.75 (95% CI, 1.50--2.05, *P*\<0.001), indicating that high IMP3 expression was associated with worse CSS in the patients with solid tumors ([Figure 4A](#f4-ott-10-2849){ref-type="fig"}). The subgroup analysis stratified by cancer types showed that high IMP3 expression significantly affected the RCC (HR =1.49, 95% CI: 1.11--2.01, *P*=0.008) and urothelial carcinoma (HR =2.17, 95% CI: 1.54--3.07, *P*\<0.001). Further sensitivity analysis did not alter the significance of combined HR, which validated the outcome credibility. Eight studies that involved 979 patients reported HRs for DFS, and the effect of high IMP3 expression is presented in [Figure 4B](#f4-ott-10-2849){ref-type="fig"}. A combined analysis showed that high IMP3 expression was associated with poor DFS in solid tumors (HR =3.30, 95% CI: 1.82--5.99, *P*\<0.001).

Seven studies with 1,930 patients investigated the prognostic role of IMP3 expression in the RFS of solid tumors. Pooled results demonstrated that high IMP3 adversely influenced the RFS in patients with solid tumors (HR =2.11, 95% CI: 1.43--3.12, *P*\<0.001, [Figure 5A](#f5-ott-10-2849){ref-type="fig"}). For PFS, four studies with 457 patients were included in the analysis. A forest plot of study-specific HRs for PFS is presented in [Figure 5B](#f5-ott-10-2849){ref-type="fig"}. The combined results indicated that high IMP3 expression was significantly associated with worse PFS in solid tumors (HR =2.18, 95% CI: 1.11--4.29, *P*=0.023). In addition, five studies, including 1,613 patients, focused on the influence of IMP3 on solid tumor metastasis. Meta-analysis of these studies suggested that IMP3 expression was also associated with poor MFS (HR =4.91, 95% CI: 2.05--11.73, *P*\<0.001, [Figure 5C](#f5-ott-10-2849){ref-type="fig"}).

Discussion
==========

Over the past decades, increasing correlative studies describe the elevated IMP3 expression in human cancers, and various functional in vitro or in vivo studies provide strong evidence indicating that this oncofetal protein serves an essential role in modulating tumor cell fate.[@b6-ott-10-2849] As a molecular biomarker, IMP3 has attracted extensive attention and can be used to distinguish different prognoses, improve prediction accuracy, and better guide clinical decisions in different tumor types.[@b7-ott-10-2849] Nevertheless, the relationship between IMP3 expression and oncological outcome remains controversial and requires a consensus. Consequently, we attempted to perform a systematic review of published relevant studies and conduct a meta-analysis to clarify the prognostic value of IMP3 expression in patients with solid tumors.

In the present research, given the inclusion criteria, 53 studies involving 8,937 patients were eligible, and the HRs of cumulative survival rates were summarized quantitatively by standard meta-analysis techniques. Our results suggested that high IMP3 expression was associated with worse OS of the solid tumors. Further subgroup analysis stratified by tumor type presented detailed results as follows. The negative prognostic effects of IMP3 on OS were specifically observed in RCC, lung cancer, oral cancer, urothelial carcinoma, HCC, colorectal cancer, pancreatic cancer, gastric cancer, and ICC. Besides OS, we also investigated other frequently used survival outcomes, including CSS, DFS, RFS, PFS, and MFS. Similar influences were found for high IMP3 expression regarding the abovementioned end points, which provide a relatively comprehensive assessment of the value of IMP3 acting as a prognostic biomarker in solid tumors.

Accumulated literature suggests that IMP3 contributes to various aspects of cancer by promoting target genes expression by either preventing mRNA decay or stimulating mRNA translation. IMP3 knockdown in vitro can significantly inhibit the translation of IGF2 mRNA resulting in the marked inhibition of cell proliferation.[@b2-ott-10-2849] By using solid cancer transcriptome data, IMP3 was also found to be correlated with HMGA2 mRNA expression in a dose-dependent manner. Additional assay for elucidating the mechanism indicated that IMP3 may function as a cytoplasmic safe house and prevents miRNA-directed mRNA decay of HMGA2 during tumor progression.[@b4-ott-10-2849] Another recent study identified IMP3 as capable of directly binding the mRNAs of cyclins D1, D3, and G1 in vivo and in vitro. The study also found that IMP3 can regulate the expression of these cyclins depending on their protein partner HNRNPM in six human cancer cell lines of different origins.[@b68-ott-10-2849] In addition, IMP3 promotes tumor cell invasion and migration by targeting the epithelial--mesenchymal transition-associated molecular makers, including E-cadherin, Slug, and vimentin.[@b69-ott-10-2849] Overall, IMP3 plays an essential and multifaceted role in human cancers. Hence, targeting IMP3 may serve as a potential strategy for anticancer therapy.

To our knowledge, our study is the first meta-analysis that comprehensively evaluated the association between IMP3 expression and prognosis in patients with solid tumors. However, several limitations of our study must be acknowledged. First, we only extracted summarized population-level data rather than individual subject data from published literature. Second, different cutoff values and definitions of high IMP3 expression were used in these included studies. Third, a marked study heterogeneity existed in some analyses. The subgroup analyses and meta-regression revealed that cancer stage might be a significant contributor to heterogeneity. Moreover, several potential factors such as cancer type, cutoff value, baseline characteristics (sample size, sex, age, and pathological subtype), and duration of follow-up may partially contribute to the heterogeneity. Among the enrolled studies, 10 works did not directly report the HRs. The calculated HRs, which were estimated using the methods of Tierney et al, might not be as dependable as those retrieved directly from the reported results. As such, the HRs inevitably introduced some statistical errors and may have influenced the pooled analysis. Furthermore, some studies only provided univariate analysis results, which may have introduced a bias toward overestimation of the prognostic value compared with multivariate analysis. The funnel plot and Egger's test suggested the probability of publication bias because of fewer studies reporting negative results. However, the greater difficulty in publishing studies with insignificant results than those with significant results may be unavoidable. Finally, despite the well-recognized advantages of systematic review and meta-analysis, the results were based on the quality of the included studies. Thus, further high-quality studies with larger samples and a unified detection method are entailed to achieve a consensus on this matter.

Conclusion
==========

The current evidence suggests that high IMP3 expression in tumor tissues is associated with adverse survival in various cancers. Hence, IMP3 might be a potential and promising biomarker that can be used to improve prognosis stratification and guide decision making in the treatment of solid tumors. Further well-designed studies are needed to confirm our findings and obtain more precise evaluations of the prognostic value of IMP3 in cancers.
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======================
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Checklist of PRISMA 2009

  Section/topic                        \#   Checklist item                                                                                                                                                                                                                                                                                                Reported on page \#
  ------------------------------------ ---- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------
  **Title**                                                                                                                                                                                                                                                                                                                                               
  Title                                1    Identify the report as a systematic review, meta-analysis, or both.                                                                                                                                                                                                                                           1
  **Abstract**                                                                                                                                                                                                                                                                                                                                            
  Structured summary                   2    Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.   2
  **Introduction**                                                                                                                                                                                                                                                                                                                                        
  Rationale                            3    Describe the rationale for the review in the context of what is already known.                                                                                                                                                                                                                                3
  Objectives                           4    Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).                                                                                                                                                    3,4
  **Methods**                                                                                                                                                                                                                                                                                                                                             
  Protocol and registration            5    Indicate if a review protocol exists, if and where it can be accessed (eg, Web address), and, if available, provide registration information including registration number.                                                                                                                                   No
  Eligibility criteria                 6    Specify study characteristics (eg, PICOS, length of follow-up) and report characteristics (eg, years considered, language, publication status) used as criteria for eligibility, giving rationale.                                                                                                            4,5
  Information sources                  7    Describe all information sources (eg, databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.                                                                                                                                      4
  Search                               8    Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.                                                                                                                                                                                 4
  Study selection                      9    State the process for selecting studies (ie, screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).                                                                                                                                                       5
  Data collection process              10   Describe method of data extraction from reports (eg, piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.                                                                                                                                      5
  Data items                           11   List and define all variables for which data were sought (eg, PICOS, funding sources) and any assumptions and simplifications made.                                                                                                                                                                           5,6
  Risk of bias in individual studies   12   Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.                                                                                        5,6
  Summary measures                     13   State the principal summary measures (eg, risk ratio, difference in means).                                                                                                                                                                                                                                   5,6
  Synthesis of results                 14   Describe the methods of handling data and combining results of studies, if done, including measures of consistency (eg, *I*^2^) for each meta-analysis.                                                                                                                                                       6
  Risk of bias across studies          15   Specify any assessment of risk of bias that may affect the cumulative evidence (eg, publication bias, selective reporting within studies).                                                                                                                                                                    6
  Additional analyses                  16   Describe methods of additional analyses (eg, sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.                                                                                                                                                                6
  **Results**                                                                                                                                                                                                                                                                                                                                             
  Study selection                      17   Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.                                                                                                                                               7
  Study characteristics                18   For each study, present characteristics for which data were extracted (eg, study size, PICOS, follow-up period) and provide the citations.                                                                                                                                                                    7
  Risk of bias within studies          19   Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).                                                                                                                                                                                                     7--14
  Results of individual studies        20   For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group; (b) effect estimates and confidence intervals, ideally with a forest plot.                                                                                                     7--14
  Synthesis of results                 21   Present results of each meta-analysis done, including confidence intervals and measures of consistency.                                                                                                                                                                                                       7--14
  Risk of bias across studies          22   Present results of any assessment of risk of bias across studies (see item 15).                                                                                                                                                                                                                               7--14
  Additional analysis                  23   Give results of additional analyses, if done (eg, sensitivity or subgroup analyses, meta-regression \[see Item 16\]).                                                                                                                                                                                         7--14
  **Discussion**                                                                                                                                                                                                                                                                                                                                          
  Summary of evidence                  24   Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (eg, healthcare providers, users, and policy makers).                                                                                                                            14,15
  Limitations                          25   Discuss limitations at study and outcome level (eg, risk of bias), and at review-level (eg, incomplete retrieval of identified research, reporting bias).                                                                                                                                                     15,16
  Conclusions                          26   Provide a general interpretation of the results in the context of other evidence, and implications for future research.                                                                                                                                                                                       17
  **Funding**                                                                                                                                                                                                                                                                                                                                             
  Funding                              27   Describe sources of funding for the systematic review and other support (eg, supply of data); role of funders for the systematic review.                                                                                                                                                                      None

**Notes:** Reproduced from Moher D, Liberati A, Tetzlaff J, et al, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. *PLoS Med*. 2009:6(7): e1000097.[@b70-ott-10-2849]
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![Forest plot of studies evaluating HR of high IMP3 expression in solid tumors for OS.\
**Notes:** A pooled analysis showed that high IMP3 expression was associated with poor OS in solid tumors (HR =2.08, 95% CI: 1.80--2.42, *P*\<0.001). Weights are from random-effects analysis.\
**Abbreviations:** CI, confidence interval; HRs, hazard ratios; IMP3, insulin-like growth factor II mRNA-binding protein 3; OS, overall survival.](ott-10-2849Fig2){#f2-ott-10-2849}

![Subgroup analysis of OS stratified by tumor types, funnel plot of OS for publication bias, and sensitive analysis of OS.\
**Notes:** (**A**) High IMP3 expression was significantly associated with poor OS in RCC, lung cancer, oral cancer, urothelial carcinoma, HCC, colorectal cancer, pancreatic cancer, gastric cancer, and ICC but not in ovarian cancer. (**B**) The funnel plot for OS was asymmetric, which indicated the probability of publication bias. (**C**) Sensitivity analysis by sequential omission of individual studies did not alter the significance, which confirmed the credibility of outcomes.\
**Abbreviations:** CI, confidence interval; HCC, hepatocellular carcinoma; HR, hazard ratio; ICC, intrahepatic cholangiocarcinoma; In, natural logarithm; IMP3, insulin-like growth factor II mRNA-binding protein 3; OS, overall survival; RCC, renal cell carcinoma; SE, standard error.](ott-10-2849Fig3){#f3-ott-10-2849}

![Forest plot of studies evaluating HRs of high IMP3 expression in solid tumors for CSS and DFS.\
**Notes:** (**A**) High IMP3 expression was associated with poor CSS in solid tumors (HR =1.75, 95% CI: 1.50--2.05, *P*\<0.001). (**B**) High IMP3 expression was associated with poor DFS in solid tumors (HR =3.30, 95% CI: 1.82--5.99, *P*\<0.001). Weights are from random-effects analysis.\
**Abbreviations:** CI, confidence interval; CSS, cancer-specific survival; DFS, disease-free survival; HRs, hazard ratios; IMP3, insulin-like growth factor II mRNA-binding protein 3; OS, overall survival.](ott-10-2849Fig4){#f4-ott-10-2849}

![Forest plot of studies evaluating HRs of high IMP3 expression in solid tumors for RFS, PFS, and MFS.\
**Notes:** (**A**) High IMP3 expression was associated with poor RFS in solid tumors (HR =2.11, 95% CI: 1.43--3.12, *P*\<0.001). (**B**) High IMP3 expression was associated with poor PFS in solid tumors (HR =2.18, 95% CI: 1.11--4.29, *P*=0.023). (**C**) High IMP3 expression was associated with poor MFS in solid tumors (HR =4.91, 95% CI: 2.05--11.73, *P*\<0.001). Weights are from random-effects analysis.\
**Abbreviations:** CI, confidence interval; HRs, hazard ratios; IMP3, insulin-like growth factor II mRNA-binding protein 3; MFS, metastasis-free survival; PFS, progression-free survival; RFS, recurrence-free survival.](ott-10-2849Fig5){#f5-ott-10-2849}

###### 

Characteristics of studies included in the meta-analysis

  Author                                 Year   Country or region           Cancer type            Case number   Method   Cutoff                                                             High expression   Follow-up                   Outcomes     Analysis   HR obtained   NOS score
  -------------------------------------- ------ --------------------------- ---------------------- ------------- -------- ------------------------------------------------------------------ ----------------- --------------------------- ------------ ---------- ------------- -----------
  Jiang et al[@b8-ott-10-2849]           2006   USA                         RCC                    371           IHC      Positive vs negative[\*](#tfn1-ott-10-2849){ref-type="table-fn"}   71 (19.1%)        Median 63 months            OS MFS       Multi      Report        9
  Pei et al[@b26-ott-10-2849]            2015   USA                         RCC                    346           IHC      Positive vs negative                                               73 (21.1%)        \>10 years                  OS RFS       Multi      Report        8
  Hoffmann et al[@b25-ott-10-2849]       2008   USA                         RCC                    716           IHC      Positive vs negative                                               213 (29.7%)       9.5 years                   CSS MFS      Multi      Report        8
  Park et al[@b27-ott-10-2849]           2014   Korea                       RCC                    148           IHC      \>5% of cells stained                                              43 (29.1%)        Median 55.5 months          CSS          Multi      Report        7
  Jiang et al[@b28-ott-10-2849]          2008   USA                         RCC                    317           IHC      Positive vs negative                                               40 (12.6%)        8.8 years                   OS MFS       Multi      Report        9
  Tantravahi et al[@b29-ott-10-2849]     2015   USA                         RCC                    27            IHC      \>20% of cells stained                                             14 (51.9%)        \>2 years                   OS           Multi      Report        6
  Del Gobbo et al[@b34-ott-10-2849]      2014   Italy                       Lung cancer            74            IHC      Positive vs negative                                               24 (32.4%)        Mean 65.6 months            OS DFS       Uni        Report        7
  Sun et al[@b32-ott-10-2849]            2015   China                       Lung cancer            196           IHC      H-score \>100 (0--300)                                             83 (42.3%)        Range (16.5--69.0) months   OS DFS       Multi      Report        8
  Yan et al[@b9-ott-10-2849]             2016   China                       Lung cancer            95            IHC      \>25% of cells stained                                             39 (41.1%)        \>5 years                   OS           Multi      Report        7
  Zhang et al[@b33-ott-10-2849]          2015   China                       Lung cancer            186           IHC      \>5% of cells stained                                              139 (74.7%)       \>5 years                   OS           Multi      Report        8
  Lin et al[@b30-ott-10-2849]            2015   China                       Lung cancer            92            IHC      Positive vs negative                                               62 (67.4%)        \>5 years                   OS           Multi      Report        8
  Beljan Perak et al[@b31-ott-10-2849]   2012   Croatia                     Lung cancer            90            IHC      \>10% of cells stained                                             61 (67.8%)        \>5 years                   OS           Uni        SC            6
  Clauditz et al[@b35-ott-10-2849]       2013   Germany                     Oral cancer            145           IHC      \>10% of cells stained                                             79 (54.5%)        Mean 41.3 months            OS           Multi      Report        8
  Lin et al[@b37-ott-10-2849]            2011   Taiwan                      Oral cancer            93            IHC      \>25% of cells stained                                             51 (54.8%)        Mean 44.8 months            OS           Multi      Report        9
  Li et al[@b36-ott-10-2849]             2010   Korea                       Oral cancer            96            IHC      Positive vs negative                                               65 (67.7%)        Median 73 months            OS           Multi      Report        9
  Kim and Cha[@b10-ott-10-2849]          2011   Korea                       Oral cancer            95            IHC      Positive vs negative                                               67 (70.5%)        \>5 years                   OS           Multi      Report        7
  Szarvas et al[@b40-ott-10-2849]        2012   Germany                     Urothelial carcinoma   106           IHC      Staining index \>7 (0--9)                                          17 (16.0%)        Median 15 months            OS CSS MFS   Multi      Report        7
  Sitnikova et al[@b39-ott-10-2849]      2008   USA                         Urothelial carcinoma   214           IHC      Positive vs negative                                               42 (19.6%)        Median 35 months            PFS DFS      Multi      Report        8
  Lee et al[@b41-ott-10-2849]            2013   Multicenter                 Urothelial carcinoma   622           IHC      Positive vs negative                                               76 (12.2%)        Median 27 months            OS CSS RFS   Multi      Report        9
  Niedworok et al[@b38-ott-10-2849]      2015   Germany                     Urothelial carcinoma   26            IHC      H-score \>100 (0--300)                                             7 (26.9%)         Median 50 months            OS PFS       Uni        Report        7
  Bi et al[@b43-ott-10-2849]             2016   China                       Ovarian cancer         73            IHC      \>10% of cells stained                                             46 (63.0%)        \>5 years                   OS           Uni        SC            7
  Kobel et al[@b16-ott-10-2849]          2009   British and North America   Ovarian cancer         278           IHC      \>5% of cells stained                                              147 (52.9%)       \>4.6 years                 CSS          Multi      Report        8
  Hus et al[@b42-ott-10-2849]            2015   Taiwan                      Ovarian cancer         140           IHC      The median value (IRS: 0--9)                                       NR                Median 39 months            PFS          Multi      Report        6
  Noske et al[@b17-ott-10-2849]          2009   Germany                     Ovarian cancer         68            IHC      IRS \>6                                                            32 (47.1%)        Median 37 months            OS           Uni        SC            7
  Hu et al[@b44-ott-10-2849]             2014   China                       HCC                    160           IHC      Staining score (2--7 vs 0--1)                                      97 (60.6%)        Median 36 months            OS RFS       Uni        SC            8
  Wachter et al[@b45-ott-10-2849]        2011   Germany                     HCC                    365           IHC      Staining group (2--3 vs 0--1)                                      67 (18.4%)        Mean 23.3 months            OS           Multi      Report        7
  Chen et al[@b46-ott-10-2849]           2013   China                       HCC                    92            IHC      Positive vs negative                                               65 (70.7%)        \>3 years                   OS           Multi      Report        7
  Yuan et al[@b48-ott-10-2849]           2009   Taiwan                      Colorectal cancer      186           IHC      \>50% of cells stained                                             66 (35.5%)        Median \>5 years            OS           Multi      Report        8
  Li et al[@b49-ott-10-2849]             2009   China                       Colorectal cancer      203           IHC      Staining score (2--7 vs 0--1)                                      132 (65.0%)       Median 61 months            OS DFS       Multi      Report        9
  Lochhead et al[@b12-ott-10-2849]       2012   USA                         Colorectal cancer      671           IHC      Intense or moderate vs weak or absent                              234 (34.9%)       Median 160 months           OS CSS       Multi      Report        8
  Lin et al[@b30-ott-10-2849]            2013   China                       Colorectal cancer      186           IHC      Positive vs negative                                               143 (76.9%)       \>2 years                   OS           Multi      Report        7
  Ikenberg et al[@b15-ott-10-2849]       2010   Switzerland                 Prostate cancer        425           IHC      Positive vs negative                                               354 (83.3%)       Median 63 months            RFS          Uni        Report        9
  Chromecki et al[@b14-ott-10-2849]      2011   USA                         Prostate cancer        232           IHC      \>10% of cells stained                                             42 (18.1%)        Median 69.8 months          RFS          Multi      Report        9
  Szarvas et al[@b50-ott-10-2849]        2014   Germany                     Prostate cancer        124           IHC      \>10% of cells stained                                             30 (24.2%)        Median 155 months           OS CSS       Uni        Report        8
  Wang et al[@b52-ott-10-2849]           2014   China                       Pancreatic cancer      50            qPCR     Cutoff value based on the ROC curve                                30 (60.0%)        \>2 years                   OS           Multi      Report        7
  Schaeffer et al[@b51-ott-10-2849]      2010   Canada                      Pancreatic cancer      127           IHC      IHC score \>5                                                      80 (63.0%)        Mean 13 months              OS           Multi      Report        8
  Morimatsu et al[@b53-ott-10-2849]      2012   Japan                       Pancreatic cancer      32            IHC      \>50% of cells stained                                             17 (53.1%)        Median 33.6 months          CSS          Uni        SC            6
  Wang et al[@b54-ott-10-2849]           2010   China                       Gastric cancer         92            IHC      Positive vs negative                                               75 (81.5%)        \>2 years                   OS           Uni        SC            7
  Okada et al[@b11-ott-10-2849]          2011   Japan                       Gastric cancer         96            IHC      \>10% of cells stained                                             71 (74.0%)        Median 5.5 years            OS DFS       Multi      Report        8
  Chen et al[@b46-ott-10-2849]           2013   Taiwan                      ICC                    61            IHC      \>10% of cells stained                                             25 (41.0%)        Mean 33.5 months            OS DFS       Uni        SC            7
  Gao et al[@b56-ott-10-2849]            2014   China                       ICC                    72            IHC      Positive vs negative                                               59 (81.9%)        Median 14.9 months          OS           Multi      Report        8
  Li et al[@b57-ott-10-2849]             2011   China                       Tongue carcinoma       65            IHC      Positive vs negative                                               50 (76.9%)        Median 36 months            CSS          Uni        SC            8
  Asioli et al[@b58-ott-10-2849]         2010   USA                         Thyroid carcinoma      103           IHC      Final score \>2 (0--6)                                             61 (59.2%)        \>5 years                   OS DFS MFS   Multi      Report        9
  Zhou et al[@b59-ott-10-2849]           2014   China                       Sacral chordoma        32            IHC      Staining score (2--7 vs 0--1)                                      20 (62.5%)        Median 110 months           DFS          Uni        SC            8
  Barton et al[@b60-ott-10-2849]         2013   USA                         PA/PMA                 77            IHC      Three groups (1--2 vs 0)                                           24 (31.2%)        Mean 8.8 years              PFS          Uni        Report        7
  Chen et al[@b61-ott-10-2849]           2011   Taiwan                      Neuroblastoma          90            IHC      \>10% of cells stained                                             52 (57.8%)        Median 39.5 months          OS           Multi      Report        8
  Hao et al[@b62-ott-10-2849]            2011   USA                         Meningioma             107           IHC      Positive vs negative                                               7 (6.5%)          Median 53 months            OS RFS       Multi      Report        7
  Sheen et al[@b63-ott-10-2849]          2014   Taiwan                      Melanoma               97            IHC      \>10% of cells stained                                             72 (74.2%)        Median 5.2 years            OS           Multi      Report        7
  Walter et al[@b64-ott-10-2849]         2009   USA                         Breast cancer          138           IHC      \>10% of cells stained                                             45 (32.6%)        Median 71.5 months          OS           Multi      Report        7
  Zhang et al[@b33-ott-10-2849]          2015   China                       Giant cell tumor       38            IHC      Staining score (3--7 vs 0--2)                                      13 (34.2%)        Median 88.0 months          RFS          Uni        SC            6
  Riener et al[@b66-ott-10-2849]         2009   Switzerland                 Bile duct carcinoma    115           IHC      Intense or moderate vs weak or absent                              67 (58.3%)        Median 9 months             CSS          Multi      Report        8
  Takata et al[@b67-ott-10-2849]         2014   Japan                       Esophageal carcinoma   191           IHC      \>10% of cells stained                                             113 (59.2%)       Mean 41 months              OS           Multi      Report        9
  Wei et al[@b13-ott-10-2849]            2014   China                       Cervical carcinoma     96            IHC      \>10% of cells stained                                             54 (56.3%)        Median 58.1 months          OS           Multi      Report        8

**Note:**

Positive vs negative: tumor cells with any detectable staining were considered positive.

**Abbreviations:** CSS, cancer-specific survival; DFS, disease-free survival; HCC, hepatocellular carcinoma; HR, hazard ratio; ICC, intrahepatic cholangiocarcinoma; IHC, immunohistochemistry; IRS, immunoreactivity score; MFS, metastasis-free survival; NOS, Newcastle--Ottawa Scale; NR, not reported; OS, overall survival; PA/PMA, pilocytic astrocytoma and pilomyxoid astrocytoma; PFS, progression-free survival; qPCR, quantitative polymerase chain reaction; RFS, recurrence-free survival; RCC, renal cell carcinoma; SC, survival curve.

###### 

Subgroup analysis and meta-regression of the studies regarding overall survival

  Subgroups                               Studies   Patients   Pooled HR and 95% CI   *P*-value   Heterogeneity (*I*^2^)   Meta-regression *P*-value
  --------------------------------------- --------- ---------- ---------------------- ----------- ------------------------ ---------------------------
  Ethnicity                                                                                                                0.748
   Caucasian                              18        3,827      2.08 (1.54--2.81)      \<0.001     76.3%                    
   Asian                                  22        2,598      1.96 (1.73--2.22)      \<0.001     9.6%                     
  No of patients                                                                                                           0.659
   \>100                                  20        4,850      2.08 (1.71--2.53)      \<0.001     62.3%                    
   \<100                                  20        1,575      2.11 (1.66--2.67)      \<0.001     57.6%                    
  Cutoff                                                                                                                   0.421
   Positive vs negative                   13        2,562      2.50 (1.96--3.19)      \<0.001     53.9%                    
   \>10% of cells stained                 11        1,201      1.95 (1.50--2.53)      \<0.001     29.7%                    
   \>25% of cells stained                 2         188        1.63 (1.06--2.52)      0.027       46.5%                    
   Others                                 14        2,474      1.87 (1.42--2.46)      \<0.001     65.6%                    
  Cancer stage                                                                                                             0.017
   Nonmetastatic                          14        2,918      2.01 (1.77--2.29)      \<0.001     23.4%                    
   Mixed (metastatic and nonmetastatic)   26        3,507      1.77 (1.58--1.97)      \<0.001     16.8%                    
  HR obtain method                                                                                                         0.326
   Reported                               34        5,881      2.14 (1.84--2.50)      \<0.001     55.5%                    
   Extracted                              6         544        1.70 (1.03--2.82)      0.040       76.2%                    
  Analysis                                                                                                                 0.319
   Univariable analysis                   9         768        1.76 (1.09--2.85)      0.020       74.7%                    
   Multivariable analysis                 31        5,657      2.14 (1.84--2.48)      \<0.001     52.9%                    

**Abbreviations:** CI, confidence interval; HR, hazard ratio.

[^1]: These authors contributed equally to this work
